July 28, 2022

BioPharmGuyNews.png

Purchase Data

Promoted Listings

Veloxity Labs is committed to treating disease one sample at a time. We are a focused LC-MS bioanalytical CRO, and we are employee-owned and operated. Our founders have over 100 years of experience.


Our experience ranges from small molecules, large molecules and microsampling. Our custom VELO™ (Veloxity Electronic Laboratory Operations) system provides for an automated workflow from first client contact through analysis and reporting of the highest quality data. VELO™ accelerates turnaround times and eliminates errors in a manual workflow.


Please contact us at www.veloxitylabs.com


Media links

LinkedIn

YouTube

BioPharmGuy


Some say the arrival of another Thursday is merely a reminder of another week gone by and how little we've grown - no matter how desperate we are that some week a better self will emerge, with each clicking of the mouse, we know it's not to be. 


And we say those people obviously have not found out about BioPharmGuy News yet. So please share this with the saddest people you know to bring them some fleeting joy every Thursday morning.


(Ok, so this first section is gonna be a bit awkward for your sad friend to read - maybe tell them to skip straight to the Industry section)


Badly Translated Email of the Week

Hi, Good day! Hope you are safety in the epidemic. Whether Pharmaceutical Projects & Equipment, or Medical Equipment, we'll be glad if we can help you. Let's work together to move forward. With sincere wish.


Companies Added & Removed

Did some catch-up on news and added 35 companies while removing three.


Tastiest New Name:

Roquefort Therapeutics


Worst New Name:

Replay


Scariest New Name:

Spiderwort 


Summary file available on our downloads page.

Industry

Zymergen

Ginkgo Bioworks acquired Zymergen for $300M, which normally would be a lot of money. However Zymergen raised over $1B before snagging another ~$500M in an IPO. And also they had, oh, about $300M cash in the bank. The enterprise value of this transaction was a big fat $0. Woof.


The next day, Zymergen axed a bunch of employees but earmarked plenty of the remaining money for executive bonuses. When you crash the ship into a sheer cliff, you still deserve that land discovery bonus, right?


Team Toast - Stripes

Ever since BioPharmGuy started roasting Team pages, it seems companies have gotten more conservative with what they're willing to put on them. Or maybe we already roasted all the best ones. Either way, we find ourselves in the uncomfortable position of resorting to complimenting companies more often.


This week we have one where the team dressed in two colors, and aligned themselves in a striped pattern. Subtle, slightly interesting...the epitome of the risk level you should take with a Team page. *soft clap*


For Sale or Lease

When a biotech company bites it, usually the website comes up for sale. Times being what they are, if you can’t quite pull together the money to buy a newly released url, it seems companies are now offering to lease them.


Would be interesting to see what might happen if you didn't pay the rent. Maybe they would 'evict' you by redirecting your website traffic to a picture of a dumpster.


X4/5

Was a rollercoaster of a month for the employees at X4 pharmaceuticals. The company obtained $55M in funding on June 30, which normally would cause a working stiff to exhale, but jump to last week and X4 decided to subtract 20% of their workforce. The good news for the victims is there are about 600 other companies in the Boston region. But damn, if a cash influx isn't even a signal of job security anymore, nothing is.


Hai Bar

Every drug company has a mission. Some go so far as to state it right on the website. Usually these are bland missives talking of making people healthier while ignoring the whole profit sideshow. Chordia Therapeutics went that route with their mission statement: 


"We are passionate to deliver first in class cancer drugs to patients."


That's suitably anodyne, but then they went a step further and delineated their goal for the year 2030:


"To be an R&D oriented pharmaceutical company based in Japan."


Nothing about having a product for sale - they just want to be doing R&D in Japan. Put another way, their 8-year goal is survival.


Flexomics

This company states they are located “in the heart of the Boston biotech ecosystem”. Kendall Square is probably the brain so that should maybe make 1 Cambridge Way the heart.


Not by the Flexomics definition. You’ll have to drive west from Kendall Square for 30 minutes (with no traffic - hahaha) to arrive at this 'heart of Boston' in Waltham, MA. 


Let’s hope anatomy isn’t pertinent to their business. 

Reduce Risk and Error Proof Your Single-Use Systems


Human error is a determining factor in a large percentage of adverse events experienced in healthcare. Single-use bioprocessing is also vulnerable to human error.


Watch this brief video and gain valuable knowledge on best practices and demonstrated error-proofing steps that you can apply in your own development and manufacturing operation.


Watch Now

Health & Science

Amyloid Scandal

Big news in Alzheimer's research. A bunch of studies from 2006 and beyond were shown to include apparently doctored images. It was another case of western blot abuse, which is probably the most common form of data fraud from that era. For those that don't know, western blotting is described by the article's authors as such:


It uses electricity to drive protein-rich tissue samples through a gel that acts like a sieve to separate the molecules by size. Distinct proteins, tagged and illuminated by fluorescent antibodies, appear as stacked bands.”


The results only have real meaning if all samples are run on the same blot simultaneously. The control/comparisons are done on the same gel at the same time because conditions can change from run to run. However, this amyloid study's authors apparently opened up photoshop and went to town.


Does it mean the whole field has been hoodwinked by the amyloid hypothesis for a decade as a result of this malfeasance? Absolutely not. Derek Lowe gives an excellent account of the history and what this particular research meant. The amyloid research tsunami would have happened anyways and the years would have been wasted regardless.


Hopefully this helps put the nail in the coffin of this failed theory so more federal research money can be allocated to interesting and, hopefully more fruitful avenues of Alzheimer's research.


Wuhan All In Check (Again)

The pandemic has come full circle as the Chinese city of Wuhan was partially locked down in the face of the irrepressible Omicron variant. The flailing zero-Covid strategy will likely carry on through the expected re-selection of Xi Jinping as China's leader at the end of 2022. Until then, we wish everyone in China the best of luck in their lockdown prep.


Three More Plagues

The WHO has officially labeled monkeypox a global health emergency. Thought not an STD, it was initially spread mostly by sexual activity amongst men. As with a more famous scourge from the 1980s, that last detail is not so relevant once it begins spreading beyond the initial group. This is still not on par with a respiratory illness like covid and never will be, but it should at least be an eye-opener for anyone who swaps fluids with strangers.


In other viral news, after having previously been detected in London's wastewater, a guy in New York came down with a case of polio. Officials have theorized he may have contracted it on his travels to eastern Europe. As of now, he can’t walk. If only there were something safe and effective that could have prevented this illness.


Finally, Marburg virus is trying to get some airtime as well. It is very much like Ebola in that it features a 50-88% lethality rate plus plenty of feverish bleeding. Thankfully this spreads slowly, but cases are starting to add up in Ghana. It's definitely a really bad virus, but is effectively no threat to people outside Africa.


California Raisin Cash

A couple weeks ago, Governor Gavin Newsom announced California would be funding its own insulin manufacture to the tune of $100M. There was more than a bit of naivete on display as industry outsiders, such as politicians, seem to have pretty much no clue how difficult and expensive it is to manufacture anything under cGMPs, much less larger molecules. $100M to build, staff and prepare a facility like this? Good luck.


They can always add more money - the biggest problem with the plan is probably going to be attracting expertise from the private sector. Newsom said they would work with contract manufacturers to build a plant and produce the insulin, but if it were that easy, why wouldn’t a profit-seeking drug company have elbowed into this lucrative game about a decade ago? 


Insulin manufacturers do not currently operate anywhere near California, so high-level talent will probably have to be coaxed to relocate from Indiana or North Carolina (3.23 & 5.25% state tax rates respectively), to a state with a 9.3% rate, all while their cost of living goes up massively. Our guess is this will be a slight problem. The $100M will almost certainly be spent, but whether it yields anything is a huge question mark.


Forbidden Baklava

FDA sent warning letters to a handful of companies found to be selling honey spiked with the two most popular ED drugs. They were marketing them as supplements, which is definitely not ok in America. This article links to the offending companies so you can easily go to their websites and make sure you don't buy the offending products.


Fighting the good fight over here. 

Subscribe!
If you were forwarded this email and like what you see, please join our mailing list.
BioPharmGuy is a registered trademark of Wilsonian LLC, Content © 2022 Wilsonian LLC

Promote Your Listing


Check your website's analytics - we are likely one of your top referrers. You may be able to boost those referrals further with a Premium Listing. Read more here: Promoted Listings.


Send us a message with questions or interest.